FORMULATION, CHARACTERIZATION AND OPTIMIZATION OF FOLIC ACID-TAILORED DAIDZEIN SOLID LIPID NANOPARTICLES FOR THE IMPROVED CYTOTOXICITY AGAINST COLON CANCER CELLS

SYED SUHAIB AHMED; MOHD ABDUL BAQI; MOHD ZUBAIR BABA; NATARAJAN JAWAHAR

doi:10.22159/ijap.2024v16i2.49879

Authors

SYED SUHAIB AHMED Department of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Ooty, Nilgiris, Tamil Nadu, India https://orcid.org/0000-0002-0290-2003
MOHD ABDUL BAQI Department of Pharmaceutical Biotechnology, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Ooty, Nilgiris, Tamil Nadu, India https://orcid.org/0009-0000-3711-3568
MOHD ZUBAIR BABA Department of Pharmaceutical Chemistry, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Ooty, Nilgiris, Tamil Nadu, India
NATARAJAN JAWAHAR Department of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Ooty, Nilgiris, Tamil Nadu, India https://orcid.org/0000-0003-0737-1237

DOI:

https://doi.org/10.22159/ijap.2024v16i2.49879

Keywords:

Colon cancer, Daidzein, Folic acid, Solid lipid nanoparticles, Microemulsion, Caco-2 cells

Abstract

Objective: The study aims to formulate and optimize daidzein-conjugated folic acid solid lipid nanoparticles (DZN-FA SLNs) to improve bioavailability and target site specificity for the treatment of colon cancer, a significant global health concern associated with high morbidity and mortality.

Methods: DZN-FA SLNs were prepared using the microemulsion method. They were prepared and optimized using design expert software. Physicochemical characterization like differential light scattering (DLS), Fourier transformed infrared spectroscopy (FTIR), scanning electron microscope (SEM), In vitro drug release and In vitro cell line studies and accelerated stability studies were carried out in the optimized batch formulation.

Results: The results indicated that particle size for optimized DZN-FA SLNs was in the range of 212 to 620 nm, zeta potential of-20 mV, drug entrapment efficiency of 72%. In vitro drug release for the prepared formulation showed 53% over 48 h.

Conclusion: The optimized DZN-FA SLNs could aid in a better formulation targeting colon cancer cells, thereby reducing systemic effects. The optimized DZN-FA SLNs have demonstrated excellent inhibitory properties on Caco-2 cells, with an IC₅₀ value of 10 µg/ml, offering a promising innovation in cancer treatment by providing targeted and effective therapy for colon cancer while minimizing the impact on normal cells.

Downloads

Download data is not yet available.

References

Xi Y, Xu P. Global colorectal cancer burden in 2020 and projections to 2040. Transl Oncol. 2021 Oct 1;14(10):101174. doi: 10.1016/j.tranon.2021.101174, PMID 34243011.

Conde J, Oliva N, Zhang Y, Artzi N. Local triple-combination therapy results in tumour regression and prevents recurrence in a colon cancer model. Nat Mater. 2016 Oct;15(10):1128-38. doi: 10.1038/nmat4707, PMID 27454043.

Hou Y, Jin J, Duan H, Liu C, Chen L, Huang W. Targeted therapeutic effects of oral inulin-modified double-layered nanoparticles containing chemotherapeutics on orthotopic colon cancer. Biomaterials. 2022 Apr 1;283:121440. doi: 10.1016/j.biomaterials.2022.121440, PMID 35245731.

Tuli HS, Tuorkey MJ, Thakral F, Sak K, Kumar M, Sharma AK. Molecular mechanisms of action of genistein in cancer: recent advances. Front Pharmacol. 2019;10:1336. doi: 10.3389/fphar.2019.01336, PMID 31866857.

Kim SH, Kim CW, Jeon SY, Go RE, Hwang KA, Choi KC. Chemopreventive and chemotherapeutic effects of genistein, a soy isoflavone, upon cancer development and progression in preclinical animal models. Lab Anim Res. 2014 Dec;30(4):143-50. doi: 10.5625/lar.2014.30.4.143, PMID 25628724.

Li H, Zhang M, Wang Y, Gong K, Yan T, Wang D. Daidzein alleviates doxorubicin-induced heart failure via the SIRT3/FOXO3a signaling pathway. Food Funct. 2022 Sep 22;13(18):9576-88. doi: 10.1039/d2fo00772j, PMID 36000402.

Senft D, Ronai ZEA. Adaptive stress responses during tumor metastasis and dormancy. Trends Cancer. 2016 Aug;2(8):429-42. doi: 10.1016/j.trecan.2016.06.004, PMID 27868104.

Chan KKL, Siu MKY, Jiang YX, Wang JJ, Leung THY, Ngan HYS. Estrogen receptor modulators genistein, daidzein and ERB-041 inhibit cell migration, invasion, proliferation and sphere formation via modulation of FAK and PI3K/AKT signaling in ovarian cancer. Cancer Cell Int. 2018 May 1;18(1):65. doi: 10.1186/s12935-018-0559-2, PMID 29743815.

Jaiswal PK, Keserwani S, Chakrabarty T. Lipid-polymer hybrid nanocarriers as a novel drug delivery platform. Int J Pharm Pharm Sci. 2022 Apr 1:1-12. doi: 10.22159/ijpps.2022v14i4.44038.

Rajpoot K, Jain SK. Colorectal cancer-targeted delivery of oxaliplatin via folic acid-grafted solid lipid nanoparticles: preparation, optimization, and in vitro evaluation. Artif Cells Nanomed Biotechnol. 2018 Aug 18;46(6):1236-47. doi: 10.1080/21691401.2017.1366338, PMID 28849671.

Ravanfar R, Tamaddon AM, Niakousari M, Moein MR. Preservation of anthocyanins in solid lipid nanoparticles: optimization of a microemulsion dilution method using the placket–burman and box–behnken designs. Food Chem. 2016;199:573-80. doi: 10.1016/j.foodchem.2015.12.061, PMID 26776010.

Bhosale RR, Janugade BU, Chavan DD, Thorat VM. Current perspectives on applications of nanoparticles for cancer management. Int J Pharm Pharm Sci. 2023 Nov 1:1-10. doi: 10.22159/ijpps.2023v15i11.49319.

Choi IK, Strauss R, Richter M, Yun CO, Lieber A. Strategies to increase drug penetration in solid tumors. Front Oncol. 2013;3:193. doi: 10.3389/fonc.2013.00193, PMID 23898462.

Yoo J, Park C, Yi G, Lee D, Koo H. Active targeting strategies using biological ligands for nanoparticle drug delivery systems. Cancers. 2019 May;11(5):640. doi: 10.3390/cancers11050640, PMID 31072061.

Yasir M, Sara UVS. Preparation and optimization of haloperidol-loaded solid lipid nanoparticles by box–behnken design. J Pharm Res. 2013;7(6):551-8. doi: 10.1016/j.jopr.2013.05.022.

Gidwani B, Vyas A. Preparation, characterization, and optimization of altretamine-loaded solid lipid nanoparticles using box-behnken design and response surface methodology. Artif Cells Nanomed Biotechnol. 2016;44(2):571-80. doi: 10.3109/21691401.2014.971462, PMID 25363752.

Kotmakçı M, Akbaba H, Erel G, Ertan G, Kantarcı G. Improved method for solid lipid nanoparticle preparation based on hot microemulsions: preparation, characterization, cytotoxicity, and hemocompatibility evaluation. AAPS PharmSciTech. 2017 May;18(4):1355-65. doi: 10.1208/s12249-016-0606-z, PMID 27502405.

Yassemi A, Kashanian S, Zhaleh H. Folic acid receptor-targeted solid lipid nanoparticles to enhance the cytotoxicity of letrozole through induction of caspase-3 dependent-apoptosis for breast cancer treatment. Pharm Dev Technol. 2020 Apr 20;25(4):397-407. doi: 10.1080/10837450.2019.1703739, PMID 31893979.

Ngwuluka NC, Kotak DJ, Devarajan PV. Design and characterization of metformin-loaded solid lipid nanoparticles for colon cancer. AAPS PharmSciTech. 2017 Feb;18(2):358-68. doi: 10.1208/s12249-016-0505-3, PMID 26975870.

Devi AR, MV. Donepezil hydrochloride loaded solid lipid nanoparticles: formulation, in vitro–in vivo pharmacokinetic and pharmacodynamics evaluation. Int J App Pharm. 2022 May 7:125-34. doi: 10.22159/ijap.2022v14i3.44145.

Surve C, SINGH R, Banerjee A, Patnaik S, Shidhaye S. Formulation and QBD based optimization of methotrexate-loaded solid lipid nanoparticles for an effective anti-cancer treatment. Int J App Pharm. 2021 Sep 7:132-43. doi: 10.22159/ijap.2021v13i5.42373.

Padmasree M, Vishwanath BA. Development and characterization of pegylated capecitabine liposomal formulations with anticancer activity towards colon cancer. Int J App Pharm. 2022;14(2):135-42. doi: 10.22159/ijap.2022v14i2.43658.

Lee PC, Lin CY, Peng CL, Shieh MJ. Development of a controlled-release drug delivery system by encapsulating oxaliplatin into SPIO/MWNT nanoparticles for effective colon cancer therapy and magnetic resonance imaging. Biomater Sci. 2016 Nov 15;4(12):1742-53. doi: 10.1039/C6BM00444J, PMID 27722406.

Jain A, Jain SK, Ganesh N, Barve J, Beg AM. Design and development of ligand-appended polysaccharidic nanoparticles for the delivery of oxaliplatin in colorectal cancer. Nanomedicine. 2010;6(1):179-90. doi: 10.1016/j.nano.2009.03.002, PMID 19447205.

Ozturk K, Mashal AR, Yegin BA, Calıs S. Preparation and in vitro evaluation of 5-fluorouracil-loaded PCL nanoparticles for colon cancer treatment. Pharm Dev Technol. 2017 Jul 4;22(5):635-41. doi: 10.3109/10837450.2015.1116565, PMID 26616273.

Ibrahim B, Mady OY, Tambuwala MM, Haggag YA. pH-sensitive nanoparticles containing 5-fluorouracil and leucovorin as an improved anti-cancer option for colon cancer. Nanomedicine (Lond). 2022 Mar;17(6):367-81. doi: 10.2217/nnm-2021-0423, PMID 35109714.

Prasad S, Dangi JS. Development and characterization of pH-responsive polymeric nanoparticles of SN-38 for colon cancer. Artif Cells Nanomed Biotechnol. 2016 Nov 16;44(8):1824-34. doi: 10.3109/21691401.2015.1105239, PMID 26540095.

Tummala S, Satish Kumar MN, Prakash A. Formulation and characterization of 5-fluorouracil enteric coated nanoparticles for sustained and localized release in treating colorectal cancer. Saudi Pharm J. 2015 Jul;23(3):308-14. doi: 10.1016/j.jsps.2014.11.010, PMID 26106279.

Yassin AEB, Anwer MdK, Mowafy HA, El-Bagory IM, Bayomi MA, Alsarra IA. Optimization of 5-flurouracil solid-lipid nanoparticles: a preliminary study to treat colon cancer. Int J Med Sci. 2010 Nov 22;7(6):398-408. doi: 10.7150/ijms.7.398, PMID 21103076.

Zielinska A, Ferreira NR, Feliczak Guzik A, Nowak I, Souto EB. Loading, release profile and accelerated stability assessment of monoterpenes-loaded solid lipid nanoparticles (SLN). Pharm Dev Technol. 2020 Aug 8;25(7):832-44. doi: 10.1080/10837450.2020.1744008, PMID 32204628.